Valutazione di efficacia di un antiangiogenetico (Bevacizumab)
Valutazione di efficacia di un antiangiogenetico (Bevacizumab)
Valutazione di efficacia di un antiangiogenetico (Bevacizumab)
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
endothelial growth factor or 2-methoxyestra<strong>di</strong>ol but antagonized by endothelial growth factors. Cancer Res<br />
2001; 61: 3369-72<br />
[93] Ramaswamy B, Rhoades CA, Kendra K, Hauger M, Allen J, Jhaveri S, Chen H, Cagnoni P, Eckhardt<br />
GS, Elias A, Shapiro CL, CTPE-sponsored phase II trial of bevacizumab (Avastin) in combination with<br />
docetaxel (Taxotere) in metastatic breat cancer [SABCS, oral presentation]. Breast Cancer Res Treat 2003;<br />
82:S50.<br />
[94] Overmoyer B, silverman P, Leeming R et al. A phase II trial of neoadjuvant docetaxel with or without<br />
bevacizumab in patients with locally advanced breasr cancer [ SABCS, poster presentation ].Breast Cancer<br />
Res Treat 2004; 88:S106<br />
[95] Wedam S, Low J, Yang SX, Chow CK, Choyke P, Danforth D, Hewitt SM, Berman A, Steinberg SM,<br />
Liewehr DJ, et al. Anti-angiogenic and anti-tumour effects of bevacizumab in inflammatory and locally<br />
advanced breast cancer patients. J Clin Oncol 2006; 24:769-77<br />
[96] Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA,<br />
Reimann JD, Sing AP, Langmuir V, Rugo HS. Randomized phase III trial of capecitabine compared with<br />
bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer .J Clin Oncol<br />
2005; 23:792-9<br />
[97] Relf M, LeJe<strong>un</strong>e S, Scott PA, Fox S, Smith K, Leek R, Moghaddam A, Whitehouse R, Bicknell R, Harris<br />
AL; Expression of the angiogenic factors vascular endothelial cell growth factor, acid and basic fibroblast<br />
growth factor, humour growth factor beta-1, plateled-derived endothelial cell growth factor, placenta growth<br />
factor, and pleio trophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997;<br />
57; 963-9<br />
[98] Miller KD, wang M, Gralow J, Dickler M, Cobleigh MA, Perez EA; Shenkier TN, Davidson NE. A<br />
randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first line for locally recurrent or<br />
metastatic breast cancer: a trial coor<strong>di</strong>nated by the Eastern Cooperative Oncology Group (E 2100) [ abstract<br />
3]. Breast Cancer Res Treat 2005; 94: (Suppl1): S6<br />
[99] S.Eva Singletary,Garret Walsh, Jean-Nicholas Vauthey, Steven Curley, N. Hortobagiy: A role of curative<br />
surgery in the treatment of selected patientswith metastatic breast cancer. The Oncologist April 2003; 8; 241-<br />
251<br />
[100] Miles D, Chan A, Romieu G, Dirix L Y et al: Randomized, doublet-blind, placebo controlled, phase III<br />
study of bevacizumab with docetaxel or docetaxel with placebo as first line therapy for patients with locally<br />
recurrent or metastatic breast cancer (mBC): AVADO. J Clin Oncol 26:2008 (May 20 suppl: abstr LAB1011)<br />
Maria Pittalis<br />
<strong>Valutazione</strong> <strong>di</strong> <strong>efficacia</strong> <strong>di</strong> <strong>un</strong> <strong>antiangiogenetico</strong> (<strong>Bevacizumab</strong>) associata a chemioterapia in pazienti con carcinoma<br />
della mammella metastatico<br />
Tesi <strong>di</strong> dottorato in scienze Biome<strong>di</strong>che-Epidemiologia molecolare dei tumori<br />
Università degli Stu<strong>di</strong> <strong>di</strong> Sassari<br />
88
Change language